{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:42:19Z","timestamp":1793025739745,"version":"4.5.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax, the first-generation inhibitor of the apoptosis regulator B-cell lymphoma 2 (BCL2), disrupts the interaction between BCL2 and proapoptotic proteins, promoting the apoptosis in malignant cells. Venetoclax is the mainstay of therapy for relapsed chronic lymphocytic leukemia and is under investigation in multiple clinical trials for the treatment of various cancers. Although venetoclax treatment can result in high rates of durable remission, relapse has been widely observed, indicating the emergence of drug resistance. The G101V mutation in BCL2 is frequently observed in patients who relapsed treated with venetoclax and sufficient to confer resistance to venetoclax by interfering with compound binding. Therefore, the development of next-generation BCL2 inhibitors to overcome drug resistance is urgently needed. In this study, we discovered that sonrotoclax, a potent and selective BCL2 inhibitor, demonstrates stronger cytotoxic activity in various hematologic cancer cells and more profound tumor growth inhibition in multiple hematologic tumor models than venetoclax. Notably, sonrotoclax effectively inhibits venetoclax-resistant BCL2 variants, such as G101V. The crystal structures of wild-type BCL2\/BCL2 G101V in complex with sonrotoclax revealed that sonrotoclax adopts a novel binding mode within the P2 pocket of BCL2 and could explain why sonrotoclax maintains stronger potency than venetoclax against the G101V mutant. In summary, sonrotoclax emerges as a potential second-generation BCL2 inhibitor for the treatment of hematologic malignancies with the potential to overcome BCL2 mutation\u2013induced venetoclax resistance. Sonrotoclax is currently under investigation in multiple clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023019706","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T17:41:38Z","timestamp":1704994898000},"page":"1825-1836","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Sonrotoclax overcomes BCL2 G101V mutation\u2013induced venetoclax resistance in preclinical models of hematologic malignancy"],"prefix":"10.1182","volume":"143","author":[{"given":"Jiuyang","family":"Liu","sequence":"first","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuran","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcai","family":"Feng","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Xing","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Yang","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-0673","authenticated-orcid":false,"given":"Yunhang","family":"Guo","sequence":"additional","affiliation":[{"name":"4Department of Medicinal Chemistry, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzi","family":"Sun","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Mei","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zhu","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Cheng","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaishuai","family":"Chen","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6589-061X","authenticated-orcid":false,"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Department of Translational Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyan","family":"Wan","sequence":"additional","affiliation":[{"name":"5Department of Translational Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[{"name":"6Department of Bioinformatics, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Ma","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Luan","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiying","family":"Xu","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"5Department of Translational Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Translational Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-7482","authenticated-orcid":false,"given":"Yuan","family":"Hong","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Xue","sequence":"additional","affiliation":[{"name":"4Department of Medicinal Chemistry, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yuan","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Song","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Medicinal Chemistry, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Discovery Biology, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[{"name":"7Research and Clinical Development, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Molecular Science, BeiGene (Beijing) Co, Ltd, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2024050215204420000_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","article-title":"Evading apoptosis in cancer","volume":"23","author":"Fernald","year":"2013","journal-title":"Trends Cell Biol"},{"issue":"4","key":"2024050215204420000_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"issue":"4678","key":"2024050215204420000_bib3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"issue":"6299","key":"2024050215204420000_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/348334a0","article-title":"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death","volume":"348","author":"Hockenbery","year":"1990","journal-title":"Nature"},{"issue":"16","key":"2024050215204420000_bib5","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1073\/pnas.88.16.6961","article-title":"BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death","volume":"88","author":"Hockenbery","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5324","key":"2024050215204420000_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.277.5324.370","article-title":"Inhibition of Bax channel-forming activity by Bcl-2","volume":"277","author":"Antonsson","year":"1997","journal-title":"Science"},{"issue":"3","key":"2024050215204420000_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond - mitochondrial performance in apoptosis","volume":"285","author":"Pena-Blanco","year":"2018","journal-title":"FEBS J"},{"issue":"1","key":"2024050215204420000_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.devcel.2011.06.017","article-title":"Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics","volume":"21","author":"Martinou","year":"2011","journal-title":"Dev Cell"},{"issue":"3","key":"2024050215204420000_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"2024050215204420000_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2024050215204420000_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2024050215204420000_bib12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"2024050215204420000_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S109325","article-title":"Development of venetoclax for therapy of lymphoid malignancies","volume":"11","author":"Zhu","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"2024050215204420000_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024050215204420000_bib15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024050215204420000_bib16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2024050215204420000_bib17","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024050215204420000_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"2024050215204420000_bib19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/0284186X.2021.1878388","article-title":"Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemia","volume":"60","author":"Tak\u00e1cs","year":"2021","journal-title":"Acta Oncol"},{"issue":"4","key":"2024050215204420000_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2019.09.008","article-title":"Venetoclax in lymphoid malignancies: new insights, more to learn","volume":"36","author":"Thijssen","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"2024050215204420000_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2024050215204420000_bib22","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood-2021-153747","article-title":"Identifying mechanisms associated with venetoclax resistance in multiple myeloma (MM) [abstract]","volume":"138","author":"Zhu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024050215204420000_bib23","doi-asserted-by":"crossref","first-page":"101251","DOI":"10.1016\/j.beha.2021.101251","article-title":"Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax","volume":"34","author":"Konopleva","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2024050215204420000_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2024050215204420000_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-19-0029","article-title":"Gly101Val BCL2 mutation: one step closer to understanding venetoclax resistance in CLL","volume":"9","author":"Thangavadivel","year":"2019","journal-title":"Cancer Discov"},{"issue":"24","key":"2024050215204420000_bib26","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024050215204420000_bib27","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2024050215204420000_bib28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024050215204420000_bib29","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/bjh.16069","article-title":"Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma","volume":"186","author":"Blombery","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2024050215204420000_bib30","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.041619798","article-title":"Solution structure of the antiapoptotic protein bcl-2","volume":"98","author":"Petros","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"2024050215204420000_bib31","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1021\/jacs.5b05896","article-title":"\u03b1\/\u03b2-peptide foldamers targeting intracellular protein-protein interactions with activity in living cells","volume":"137","author":"Checco","year":"2015","journal-title":"J\u00a0Am Chem Soc"},{"issue":"8","key":"2024050215204420000_bib32","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1073\/pnas.1525616113","article-title":"Structural and biochemical analysis of Bcl-2 interaction with the hepatitis B virus protein HBx","volume":"113","author":"Jiang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2024050215204420000_bib33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V108.11.1107.1107","article-title":"The Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice","volume":"108","author":"Shoemaker","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2024050215204420000_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"2024050215204420000_bib35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5517","key":"2024050215204420000_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"issue":"2","key":"2024050215204420000_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/cdd.2013.139","article-title":"Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis","volume":"21","author":"Westphal","year":"2014","journal-title":"Cell Death Differ"},{"issue":"14","key":"2024050215204420000_bib38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"2024050215204420000_bib39","unstructured":"FDA\n          . FDA Center for Drug Evaluation and Research Application Number: 208573Orig1s000 Pharmacology Review(s.). Accessed 16 November 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208573Orig1s000PharmR.pdf."},{"issue":"17","key":"2024050215204420000_bib40","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J\u00a0Med Chem"},{"key":"2024050215204420000_bib41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/DDDT.S250823","article-title":"Zanubrutinib (BGB-3111), a second-generation selective covalent inhibitor of Bruton's tyrosine kinase and its utility in treating chronic lymphocytic leukemia","volume":"15","author":"Rhodes","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2024050215204420000_bib42","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"2024050215204420000_bib43","first-page":"1000188","article-title":"Passenger mutations in cancer evolution","volume":"3","author":"Aparisi","year":"2019","journal-title":"Cancer Rep Rev"},{"issue":"2","key":"2024050215204420000_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"2024050215204420000_bib45","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2024050215204420000_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"issue":"20","key":"2024050215204420000_bib47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024050215204420000_bib48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance\u00a0to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2024050215204420000_bib49","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"suppl 12","key":"2024050215204420000_bib50","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1158\/1538-7445.AM2022-3960","article-title":"Abstract 3960: BCL-2 G101V mutations develop in one-third of patients on continuous venetoclax","volume":"82","author":"Kuang","year":"2022","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2024050215204420000_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-99-118604","article-title":"Genetic determinants of venetoclax resistance in lymphoid malignancies [abstract]","volume":"132","author":"Guieze","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024050215204420000_bib52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2019-131336","article-title":"MCL-1 and PKA\/AMPK axis fuel venetoclax resistance in lymphoid cancers [abstract]","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024050215204420000_bib53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"12","key":"2024050215204420000_bib54","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"1","key":"2024050215204420000_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","article-title":"Combining BTK\u00a0inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"issue":"25","key":"2024050215204420000_bib56","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2024050215204420000_bib57","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2024050215204420000_bib58","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","article-title":"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity","volume":"121","author":"Rudnicka","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2024050215204420000_bib59","first-page":"1183","article-title":"Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis","volume":"2","author":"Jazirehi","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2024050215204420000_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024050215204420000_bib61","first-page":"463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J\u00a0Pers Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/18\/1825\/2223764\/blood_bld-2023-019706-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/18\/1825\/2223764\/blood_bld-2023-019706-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T11:22:03Z","timestamp":1714648923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/18\/1825\/507122\/Sonrotoclax-overcomes-BCL2-G101V-mutation-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":61,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023019706","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}